Hepatic-specific DUSP22 deletion particularly exacerbates lipid deposition, inflammatory response and fibrosis in liver, facilitating NASH and non-alcoholic fatty liver disease (NAFLD)-associated HCC progression. This evidence concerns the gene DUSP22 and metabolic dysfunction-associated steatotic liver disease.